Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BECTON, DICKINSON AND COMPANY

(BDX)
  Report
Delayed Nyse  -  04:00 2022-12-02 pm EST
252.38 USD   +0.62%
11/29Transcript : Becton, Dickinson and Company Presents at 5th Annual Evercore ISI HealthCONx Conference 2022, Nov-29-2022 08:00 AM
CI
11/29Distinct Elements Or Parts Of A Whole? Obviousness Challenge Denied In SolarEdge Techs., Inc. v. Fronius Int'l GMBH
AQ
11/23AngioDynamics Disagrees With Jury Decision on Patent-Infringement Verdict, Plans to Appeal
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Becton Dickinson and : BD Launches First-in-Human Trial of Sirolimus Drug-Coated Balloon to Expand Treatment Options for Peripheral Arterial Disease

08/18/2022 | 06:44am EST

First patient enrollment in PREVISION trial marks opportunity to further advance the safety and performance of drug-coated balloon technology and aligns with the company's commitment to developing innovations that enhance Chronic Disease Outcomes

FRANKLIN LAKES, N.J., Aug. 18, 2022 - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has announced the start of enrollment in a first-in-human trial of a peripheral sirolimus drug-coated balloon (DCB).

BD is a pioneer in DCB technology as the first to gain U.S. FDA approval for a paclitaxel DCB. BD's Lutonix™, which received FDA approval in 2014, is celebrating its 10-year anniversary globally this year. Over this time, BD has continued to innovate and lead in DCB technology with advancements such as additional indications, lower sheath profile, longer treatment lengths, and additional guidewire configurations. Today, DCBs remain a broadly accepted endovascular interventional treatment option for patients with peripheral arterial disease (PAD) of the femoropopliteal artery.

"PAD impacts more than 200 million people across the globe and is often associated with morbidity, functional declines and higher health care costs.1 BD is committed to delivering much-needed solutions to address these challenges," said Paddy O'Brien, Worldwide President of BD Peripheral Intervention. "The launch of our PREVISION first-in-human study demonstrates our ongoing commitment to advancing the drug coated balloon category. It marks an important milestone on the path towards bringing this technology to clinicians and patients around the globe."

The PREVISION trial is a prospective, multicenter, single arm, non-randomized study designed to evaluate the safety of the BD sirolimus DCB in the treatment of peripheral arterial disease in the femoropopliteal arteries.

BD initiated this trial to determine the viability of sirolimus as a future treatment option for patients with PAD. The first patient was successfully treated by Dr. Andrew Holden, principal investigator at Auckland City Hospital, New Zealand.

"It is an honor to enroll the first patient in the PREVISION study," said Dr. Holden. "The burden of PAD continues to impact patients and challenge physicians around the globe. A continued focus on developing next-generation technology is important for the patients suffering from PAD."

PREVISION is being conducted across multiple sites in Australia, New Zealand, and Singapore. The trial will enroll and follow-up on approximately 50 patients over the coming months.

1 Fanaroff A, Rao S, Swaminathan R. Radial Access for Peripheral Interventions. Interventional Cardiolology Clinics. 2020;9:53-61. doi: https://doi.org/10.1016/j.iccl.2019.08.005

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

MEDIA CONTACT: INVESTOR CONTACT:
Trey Hollern Francesca DeMartino
Director, Public Relations SVP, Head of Investor Relations
862.284.8629 201.847.5743
trey.hollern@bd.comfrancesca.demartino@bd.com

Disclaimer

BD - Becton, Dickinson and Company published this content on 18 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 August 2022 10:43:03 UTC.


ę Publicnow 2022
All news about BECTON, DICKINSON AND COMPANY
11/29Transcript : Becton, Dickinson and Company Presents at 5th Annual Evercore IS..
CI
11/29Distinct Elements Or Parts Of A Whole? Obviousness Challenge Denied In SolarEdge Techs...
AQ
11/23AngioDynamics Disagrees With Jury Decision on Patent-Infringement Verdict, Plans to App..
MT
11/23Goldman Sachs Adjusts Becton, Dickinson and Co.'s Price Target to $272 From $319, Keeps..
MT
11/23Jury Hits AngioDynamics With Patent-Infringement Verdict
DJ
11/22BECTON DICKINSON & CO Management's Discussion and Analysis of Financial Condition and ..
AQ
11/15BD to Present at Evercore ISI 5th Annual HealthCONx Conference
PR
11/11Piper Sandler Adjusts Becton, Dickinson and Co.'s Price Target to $245 From $255, Keeps..
MT
11/10Becton Dickinson expects fiscal 2023 COVID test sales to drag
RE
11/10Transcript : Becton, Dickinson and Company, Q4 2022 Earnings Call, Nov 10, 20..
CI
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2023 18 776 M - -
Net income 2023 1 870 M - -
Net Debt 2023 11 802 M - -
P/E ratio 2023 36,6x
Yield 2023 1,47%
Capitalization 71 518 M 71 518 M -
EV / Sales 2023 4,44x
EV / Sales 2024 4,11x
Nbr of Employees 77 000
Free-Float 77,4%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 252,38 $
Average target price 264,42 $
Spread / Average Target 4,77%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Christopher J. DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Elizabeth McCombs Senior Vice President-Research & Development
Joseph M. Smith Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY2.06%70 657
ABBOTT LABORATORIES-23.56%187 574
MEDTRONIC PLC-23.60%105 135
DEXCOM, INC.-12.07%44 914
HOYA CORPORATION-16.60%35 959
AMERISOURCEBERGEN CORPORATION29.15%35 107